Scott P Campbell1, Alexander S Baras2, Mark W Ball1, Max Kates1, Noah M Hahn3, Trinity J Bivalacqua1,3, Michael H Johnson1, Martin G Pomper1,3,4, Mohamad E Allaf1,3, Steven P Rowe1,4, Michael A Gorin5,6,7,8,9. 1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu. 6. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu. 7. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu. 8. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mgorin1@jhmi.edu. 9. , 600 North Wolfe Street, Park 213, Baltimore, MD, 21287, USA. mgorin1@jhmi.edu.
Abstract
OBJECTIVE: To explore the clinical utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with metastatic urothelial carcinoma. METHODS: Three patients with metastatic urothelial carcinoma were imaged with 18F-DCFPyL PET/CT. All lesions with perceptible radiotracer uptake above background were considered positive. Maximum standardized uptake values were recorded for each detected lesion and findings on 18F-DCFPyL PET/CT were compared to those on conventional imaging studies. To further explore PSMA as a molecular target of urothelial carcinoma, RNA-sequencing data from The Cancer Genome Atlas were used to compare the relative expression of PSMA among cases of bladder cancer, prostate cancer, and clear cell renal cell carcinoma. Additionally, immunohistochemical staining for PSMA was performed on a biopsy specimen from one of the imaged patients. RESULTS: 18F-DCFPyL PET/CT allowed for the detection of sites of urothelial carcinoma, albeit with low levels of radiotracer uptake. Analysis of RNA-sequencing data revealed that bladder cancer had significantly lower levels of PSMA expression than both prostate cancer and clear cell renal cell carcinoma. Consistent with this observation, immunohistochemical staining of tissue from one of the imaged patients demonstrated a low level of neovascularization and nearly absent PSMA expression. CONCLUSION: The relatively scant expression of PSMA by urothelial carcinoma likely limits the utility of PSMA-targeted PET imaging of this malignancy. Future research efforts should focus on the development of other molecularly targeted imaging agents for urothelial carcinoma.
OBJECTIVE: To explore the clinical utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with metastatic urothelial carcinoma. METHODS: Three patients with metastatic urothelial carcinoma were imaged with 18F-DCFPyL PET/CT. All lesions with perceptible radiotracer uptake above background were considered positive. Maximum standardized uptake values were recorded for each detected lesion and findings on 18F-DCFPyL PET/CT were compared to those on conventional imaging studies. To further explore PSMA as a molecular target of urothelial carcinoma, RNA-sequencing data from The Cancer Genome Atlas were used to compare the relative expression of PSMA among cases of bladder cancer, prostate cancer, and clear cell renal cell carcinoma. Additionally, immunohistochemical staining for PSMA was performed on a biopsy specimen from one of the imaged patients. RESULTS:18F-DCFPyL PET/CT allowed for the detection of sites of urothelial carcinoma, albeit with low levels of radiotracer uptake. Analysis of RNA-sequencing data revealed that bladder cancer had significantly lower levels of PSMA expression than both prostate cancer and clear cell renal cell carcinoma. Consistent with this observation, immunohistochemical staining of tissue from one of the imaged patients demonstrated a low level of neovascularization and nearly absent PSMA expression. CONCLUSION: The relatively scant expression of PSMA by urothelial carcinoma likely limits the utility of PSMA-targeted PET imaging of this malignancy. Future research efforts should focus on the development of other molecularly targeted imaging agents for urothelial carcinoma.
Authors: Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Boben Thomas; K R Vikraman Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-08 Impact factor: 9.236
Authors: Laura S Mertens; Richard P Meijer; Wim Meinhardt; Henk G van der Poel; Axel Bex; J Martijn Kerst; Michiel S van der Heijden; Andries M Bergman; Simon Horenblas; Bas W G van Rhijn Journal: BJU Int Date: 2014-01-17 Impact factor: 5.588
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: J L Gala; S Loric; Y Guiot; S R Denmeade; A Gady; F Brasseur; M Heusterspreute; P Eschwège; P De Nayer; P Van Cangh; B Tombal Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf Journal: Ann Nucl Med Date: 2015-08-19 Impact factor: 2.668
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Chaitanya R Divgi; Eze A Wills; Lawrence Schwartz; Mithat Gönen; Peter Smith-Jones; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris Journal: EJNMMI Res Date: 2015-04-29 Impact factor: 3.138
Authors: Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: Henner Schreiber; Jörg Hänze; Wilhelm Nimphius; Frederik Anton Verburg; Markus Luster; Rainer Hofmann; Axel Hegele Journal: J Cancer Res Clin Oncol Date: 2020-01-02 Impact factor: 4.553
Authors: Panagiotis J Vlachostergios; Christopher D Jakubowski; Muhammad J Niaz; Aileen Lee; Charlene Thomas; Amy L Hackett; Priyanka Patel; Naureen Rashid; Scott T Tagawa Journal: Bladder Cancer Date: 2018-07-30
Authors: Marga Garrido Siles; Antonio López-Beltran; Paula Pelechano; Ana María García Vicente; Regina Gironés Sarrió; Eva González-Haba Peña; Alfredo Rodríguez Antolín; Almudena Zapatero; José Ángel Arranz; Miguel Ángel Climent Journal: Cancers (Basel) Date: 2022-08-17 Impact factor: 6.575
Authors: Christophe Van de Wiele; Mike Sathekge; Bart de Spiegeleer; Pieter Jan de Jonghe; Laurence Beels; Alex Maes Journal: Int J Mol Sci Date: 2019-10-02 Impact factor: 5.923
Authors: Vera Wenter; Alexander Kretschmer; Lena M Unterrainer; Simon Lindner; Lennert Eismann; Jozefina Casuscelli; Franz-Josef Gildehaus; Vinh Ngoc Bui; Nathalie L Albert; Adrien Holzgreve; Leonie Beyer; Andrei Todica; Matthias Brendel; Clemens C Cyran; Alexander Karl; Christian G Stief; Stephan T Ledderose; Marcus Unterrainer; Peter Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2022-03-24 Impact factor: 10.057